Sep 07, 2023 / 07:00PM GMT
Yanan Zhu - Wells Fargo Securities - Analyst
Great. Thanks everyone for being here. My name is Yanan Zhu, and I'm one of the biotech analysts here at Wells Fargo. It's our privilege to have Editas Medicine's management team with us for our fireside chat here today.
With me here are Gilmore O'Neill, Chief Executive Officer; and Baisong Mei, Chief Medical Officer. Thank you, Baisong. Thank you, Gilmore, for being here.
Gilmore O'Neill - Editas Medicine, Inc. - President & CEO
Thank you very much for having us.
Baisong Mei - Editas Medicine, Inc. - SVP & Chief Medical Officer
Thank you.
Questions and Answers:
Yanan Zhu - Wells Fargo Securities - AnalystGreat. So, I think -- if we could, let's dive right into EDIT-301 for sickle cell disease and the ongoing RUBY trial, if that's okay. Wondering, how many sites have been opened? How many patients have been enrolled? And how many have been dosed?
Gilmore O'
Trustpilot
